Japan Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook

The gastroesophageal reflux disease therapeutics market in Japan is expected to reach a projected revenue of US$ 345.6 million by 2030. A compound annual growth rate of 1.2% is expected of Japan gastroesophageal reflux disease therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$318.7
Forecast, 2030 (US$M)
$345.6
CAGR, 2024 - 2030
1.2%
Report Coverage
Japan

Japan gastroesophageal reflux disease therapeutics market, 2018-2030 (US$M)

Japan

Related Markets

Japan gastroesophageal reflux disease therapeutics market highlights

  • The Japan gastroesophageal reflux disease therapeutics market generated a revenue of USD 318.7 million in 2023 and is expected to reach USD 345.6 million by 2030.
  • The Japan market is expected to grow at a CAGR of 1.2% from 2024 to 2030.
  • In terms of segment, antacids was the largest revenue generating drug type in 2023.
  • H2 Receptor Blockers is the most lucrative drug type segment registering the fastest growth during the forecast period.


Gastroesophageal reflux disease therapeutics market data book summary

Market revenue in 2023USD 318.7 million
Market revenue in 2030USD 345.6 million
Growth rate1.2% (CAGR from 2023 to 2030)
Largest segmentAntacids
Fastest growing segmentH2 Receptor Blockers
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAntacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents
Key market players worldwideAstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares


Other key industry trends

  • In terms of revenue, Japan accounted for 6.0% of the global gastroesophageal reflux disease therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China gastroesophageal reflux disease therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 468.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Gastroesophageal Reflux Disease Therapeutics Market Companies

Name Profile # Employees HQ Website

Japan gastroesophageal reflux disease therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.


Antacids was the largest segment with a revenue share of 56.64% in 2023. Horizon Databook has segmented the Japan gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.


Elderly population is highly susceptible to gastric reflux, and Japan has the largest geriatric population. According to an article published in by S. Karger AG in the International Journal of Gastroenterology in 2016.

Acid reflux-related symptoms were reported in 6.6% to 9.8% of population on a monthly basis and a majority of erosive esophagitis patients had mild GERD. More than 50% of these patients suffered from nonerosive reflux disease and erosive esophagitis.

Reasons to subscribe to Japan gastroesophageal reflux disease therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan gastroesophageal reflux disease therapeutics market databook

  • Our clientele includes a mix of gastroesophageal reflux disease therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan gastroesophageal reflux disease therapeutics market outlook size, by drug type, 2018-2030 (US$M)

Japan Gastroesophageal Reflux Disease Therapeutics Market Outlook Share, 2023 & 2030 (US$M)

Japan gastroesophageal reflux disease therapeutics market outlook size, by drug type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more